Publications

TGFß in GI Fibrosis

Sáez-Borderías, A., T Van Kaem, J Alberti, P J Stiers, C Sabadie, R Van Heeswijk, T Senso, B Pampín, R Bosser, P Wiesel. AGMB-129, an investigational ALK5 inhibitor for the treatment of Fibrostenosing Crohn’s Disease (FSCD), shows gastrointestinal (GI) restricted pharmacokinetics (PK) and a favorable safety profile in healthy subjects. ECCO 2025 Poster Presentation , Berlin, Germany; February 19-22, 2025.

TGFß in IPF

TGFß in Liver Fibrosis

Toxicity of systemic TGFß blockade

HGF/ MET Pathway Overview

HGF/ MET Pathway in Disease

Disclaimer

The publications reflect historical data. Agomab does not warrant that these data are accurate, complete or up-to-date as of the date you access such publications. All Agomab product candidates mentioned in these publications are investigational in nature and have not been approved yet by any regulatory authority. Their efficacy and safety have not been established. The content of these publications is not intended for patients. Patients should always consult with a doctor or other healthcare professionals for medical advice or information about diagnosis and treatment.